Company news

Racura Oncology Ltd news in 2021

Racura Oncology Ltd's news releases, calls and decks from 2021, newest first.

View company

Race raises $29.7 million in oversubscribed SPP

December 20, 2021

Expanded Heart Protection Discovery for Zantrene

December 7, 2021

Race Oncology: Notification regarding unquoted securities - RAC

December 3, 2021

Race Oncology Investor Presentation - November 2021

November 23, 2021

Race Oncology Share Purchase Plan

November 23, 2021

AGM Presentations

November 22, 2021

Breakthrough Zantrene Heart Protection Discovery

November 21, 2021

University of Wollongong R&D Collaboration

November 8, 2021

Race secures sixth US patent for Zantrene

October 18, 2021

Race secures fifth US patent for Zantrene

October 5, 2021

Preclinical & Clinical Programs Update

September 30, 2021

Zantrene highly effective in Melanoma preclinical study

September 29, 2021

First Patient Dosed in Phase 1b/2 AML Trial

August 9, 2021

Race executes Israel AML Phase 2 Trial Contract

June 21, 2021

Race Executes Key Contract for Israel Phase 2 AML Trial

June 7, 2021

Contract to Commence Phase 2 Extramedullary AML Trial

June 1, 2021

Prospectus

May 5, 2021

Placement closes oversubscribed-Bonus Option Issue launched

May 4, 2021

Race investor briefing & updated presentation

May 4, 2021

Race Initiates Heart Safety Preclinical Study for Bisantrene

April 27, 2021

Second independent study shows Bisantrene inhibits FTO

April 15, 2021

Race Strategic Update March 2021

March 30, 2021

Race Initiates Extramedullary AML Preclinical Study

March 29, 2021

Race Initiates FTO Directed Kidney Cancer Preclinical Study

March 24, 2021

Race Initiates FTO Melanoma Preclinical Study

March 18, 2021

S&P DJI Announces March 2021 Quarterly Rebalance

March 12, 2021

Compelling Preclinical Breast Cancer Results

March 8, 2021

Decks in 2021